secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001213900-25-112644
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model
--------------------------------------------------------------------------------

- Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.
- Neurological assessments found no adverse effects on attitude, behavior, or motor function.
- Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.
- Data support design of first-in-human Phase 1 clinical trial for INM-901.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/0001213900-25-112644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025112644/ea0266453-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-112644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer